The Preventive Value of Acupoint Sensitization Based on Stable Angina Pectoris

The Preventive Value of Acupoint Sensitization Based on Stable Angina Pectoris

This study, taking stable angina pectoris as a research carrier, aims to explore the preventive value of acupoint sensitization by conducting a double-blind multi-center randomized controlled trial to compare the effect of stimulating acupoints with different sensitivity on the prevention of angina pectoris.

After the inclusion of eligible patients, the pressure-pain threshold of disease-related acupoints will be detected by using Von Frey detector. Then, the patients will be randomly divided into experimental group and control group. The patients in experimental group will be given acupoints pressure on the five acupoints with the lowest pressure-pain threshold, while the patients in control group will be given acupoints pressure on the five acupoints with the five acupoints with the highest pressure-pain threshold. The two groups will be treated with acupoints pressure 12 times within 4 weeks. The patients will be evaluated three times at baseline, the end of treatment and four weeks after the end of treatment respectively, including angina attack frequency, CCS classification and SAQ score.

Inclusion Criteria:

• Patients with stable angina pectoris and symptoms of chest pain
• The duration of onset was more than 3 months, and the number of angina attacks in the past month was not less than 2
• Not younger than 35 years old and not older than 80 years old
• Patients will participate in the study voluntarily and have signed the informed consent

Exclusion Criteria:

• Patients with mental retardation
• Patients were contraindicated or unable to complete acupoint sensitization test
• Patients with cardiovascular, digestive, urinary, respiratory, blood, nervous, endocrine system and other serious primary diseases
• Patients with bleeding, allergy constitution
• Patients with abnormal skin or peripheral nerve sensation, abnormal pain sensation, skin ulceration at the sensitization detection site
• Patients with unsatisfactory clinical treatment of hypertension and diabetes